| Market Cap | 128.54M | P/E | - | EPS this Y | 17.20% | Ern Qtrly Grth | - |
| Income | -65.44M | Forward P/E | -1.94 | EPS next Y | 51.00% | 50D Avg Chg | -25.00% |
| Sales | 23.82M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -47.00% |
| Dividend | N/A | Price/Book | 0.88 | EPS next 5Y | - | 52W High Chg | -64.00% |
| Recommedations | 3.00 | Quick Ratio | 3.82 | Shares Outstanding | 24.61M | 52W Low Chg | 3.00% |
| Insider Own | 10.79% | ROA | -34.93% | Shares Float | 14.14M | Beta | 0.35 |
| Inst Own | 60.18% | ROE | -62.26% | Shares Shorted/Prior | 394.12K/302.63K | Price | 5.26 |
| Gross Margin | -128.40% | Profit Margin | -274.77% | Avg. Volume | 126,200 | Target Price | 1.63 |
| Oper. Margin | -252.21% | Earnings Date | Nov 6 | Volume | 224,819 | Change | 0.19% |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Piper Sandler | Neutral | Aug 27, 24 |
| HC Wainwright & Co. | Neutral | Aug 21, 24 |
| TD Cowen | Hold | Aug 21, 24 |
| HC Wainwright & Co. | Neutral | May 14, 24 |
| Piper Sandler | Overweight | Dec 15, 23 |
| HC Wainwright & Co. | Neutral | Dec 15, 23 |
| HC Wainwright & Co. | Buy | Nov 13, 23 |
| HC Wainwright & Co. | Buy | Aug 10, 23 |
| HC Wainwright & Co. | Buy | Jun 8, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Desai Neil | Executive Chairman Executive Chairman | Feb 01 | Sell | 1.7445 | 42,000 | 73,269 | 1,453,543 | 02/02/24 |
| Desai Neil | Executive Chairman Executive Chairman | Jan 02 | Sell | 2.0607 | 42,000 | 86,549 | 1,495,543 | 01/02/24 |
| Desai Neil | Executive Chairman Executive Chairman | Dec 01 | Sell | 5.1 | 34,963 | 178,311 | 1,544,580 | 12/05/23 |
| Desai Neil | Executive Chairman Executive Chairman | Nov 01 | Sell | 4.39 | 42,000 | 184,380 | 1,579,543 | 11/02/23 |
| Desai Neil | Executive Chairman Executive Chairman | Oct 02 | Sell | 4.23 | 42,000 | 177,660 | 1,621,543 | 10/03/23 |
| Desai Neil | Executive Chairman Executive Chairman | Sep 01 | Sell | 5.63 | 42,000 | 236,460 | 1,663,543 | 09/06/23 |
| Desai Neil | Executive Chairman Executive Chairman | Jul 03 | Sell | 6.49 | 42,000 | 272,580 | 1,747,543 | 07/06/23 |
| Desai Neil | Executive Chairman Executive Chairman | Jun 06 | Sell | 8.1891 | 7,260 | 59,453 | 1,789,543 | 06/06/23 |
| Desai Neil | Executive Chairman Executive Chairman | Jun 01 | Sell | 8.01 | 34,740 | 278,267 | 1,796,803 | 06/05/23 |
| Desai Neil | Executive Chairman Executive Chairman | May 01 | Sell | 7.65 | 39,695 | 303,667 | 1,833,848 | 05/03/23 |
| Desai Neil | Executive Chairman Executive Chairman | Apr 06 | Sell | 7.0927 | 12,212 | 86,616 | 1,873,543 | 04/06/23 |
| Desai Neil | Executive Chairman Executive Chairman | Apr 03 | Sell | 7.33 | 29,788 | 218,346 | 1,885,755 | 04/05/23 |
| Desai Neil | See Remarks See Remarks | Mar 18 | Sell | 20.0658 | 3,550 | 71,234 | 1,915,543 | 03/22/22 |